Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Total Debt
Short-term and long-term borrowings combined.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 143.8% from a year ago
Total debt stood at $1.44M at the end of Q1 FY2026, up 143.8% from a year earlier and down 15.7% from the prior quarter.
Context
- Total debt amounted to 0.3% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Total debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +143.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 1.71M USD
- Year-over-year change
- +131.7%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.71M | +131.7% |
| FY2024 | 2024-12-31 | 738K | +12.3% |
| FY2023 | 2023-12-31 | 657K | — |
| FY2022 | 2022-12-31 | 0 | — |
Total Debt vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 total debt of $1.44M is the 5th highest of the 6 companies compared; the peer median is $2.38M.
- Its year-over-year change of +143.8% is the highest of 5, against a peer median of +37.7%.
- Total debt amounts to 0.3% of total assets for BCAX, versus a peer median of 0.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $36.51M | -2.6% | +45.3% | 16.8% | |
| Mar 2026 | $9.79M | +53.4% | +49.6% | 4.8% | |
| Mar 2026 | $2.38M | +29.5% | -19.7% | 0.6% | |
| Mar 2026 | $1.54M | — | +21.4% | 0.8% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $1.44M | +143.8% | — | 0.3% |
| Mar 2026 | $282.42K | +45.8% | +26.7% | 0.5% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $2.38M | +37.7% | +26.7% | 0.8% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.